Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole

Author： Albrecht Stefan   Buerger Erich  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.12, 2009-12, pp. : 2977-2987

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 13, 2015-11 ,pp. : 1859-1860

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia

By  

Reviews on Recent Clinical Trials, Vol. 13, Iss. 1, 2018-01 ,pp. : 37-44

Bentham Science Publishers

Access to resources Recommend Favorite

Transdermal Dopamine Agonist Ameliorates Gastric Emptying in Parkinson's Disease

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 11, 2015-11 ,pp. : 2416-2418

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rotigotine is potent agonist at D1 receptors

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 4, 2015-02 ,pp. : 1124-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dantrolene: Mechanisms of Neuroprotection and Possible Clinical Applications in the Neurointensive Care Unit

By Muehlschlegel Susanne  

Neurocritical Care, Vol. 10, Iss. 1, 2009-02 ,pp. : 103-115

Humana Press, Inc

Access to resources Recommend Favorite